文献速递血栓与止血

成人及儿童ITP血小板、出血与生活质量结局指标差异巨大:ISTH SSC血小板免疫学分会报告

Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology.
PubMed 文献 · J Thromb Haemost · 2021-06-08

该研究系统检索2010至2019年PubMed/MEDLINE文献,纳入168项成人及儿童ITP研究,分析血小板、出血及健康相关生活质量(HRQoL)结局指标的使用情况。结果显示,57%的血小板反应研究未采用ITP国际工作组(IWG)定义,出血结局仅41%系统报告,HRQoL仅9%报告,且各结局指标定义高度异质。

要点

  • 多数ITP研究未采用IWG标准定义血小板反应,随机试验更倾向以血小板≥50×10^9/L定义反应。
  • 出血结局仅41%研究系统报告,成人多用WHO出血量表,儿童多用Buchanan and Adix评分。
  • HRQoL结局报告率仅9%,共使用8种不同量表,标准化需求迫切。

核心结论

  • 尽管已有标准化建议,ITP研究在血小板、出血和HRQoL结局指标上仍存在广泛异质性。
  • 多数ITP研究未系统评估出血或HRQoL结局,亟需进一步标准化。

研究设计与样本

  • 检索获得1562篇文献,最终168篇符合纳入标准。
  • 项目由ISTH血小板免疫学SSC批准。

主要发现

  • 141项研究报告血小板反应结局,其中57%未使用IWG定义,采用了21种不同的替代方案。
  • 多数随机试验未用IWG定义,而采用血小板≥50×10^9/L定义反应。
  • 无治疗情况下血小板≥100×10^9/L持续≥6个月是最常见的ITP缓解定义。
  • 41%的研究系统报告出血结局,使用了21种不同报告方案。
  • HRQoL结局仅在9%的研究中报告,共使用8种不同HRQoL工具。

关键数值与推荐

  • 血小板反应:57%研究未用IWG定义,随机试验多采用血小板≥50×10^9/L。
  • ITP缓解:无治疗下血小板≥100×10^9/L持续≥6个月为最常见定义。
  • 出血评估:成人多用WHO出血量表,儿童多用Buchanan and Adix评分。

临床怎么用

  • 解读ITP研究结果时需注意结局定义异质性,避免直接比较不同定义下的反应率。
  • 临床实践中可参考IWG定义评估血小板反应,但需了解现有研究多未采用统一标准。
  • 出血和HRQoL应作为系统评估的结局指标,尤其在临床试验设计中。

局限性

  • 仅纳入PubMed/MEDLINE索引文献,可能遗漏其他数据库发表的研究。
  • 检索时间范围为2010至2019年,未涵盖更近期文献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Despite publication of standardization recommendations by the immune thrombocytopenia (ITP) International Working Group (IWG) in 2009, there remains inconsistent outcomes definitions across ITP studies. To understand current practices and inform future standardization efforts, we characterized how outcomes have been measured following publication of IWG recommendations. METHODS: PubMed/MEDLINE-indexed manuscripts published from January 2010 through December 2019 describing platelet, bleeding, and/or health-related quality of life (HRQoL) outcome measures in adult and pediatric ITP were comprehensively reviewed. This project was endorsed by the Platelet Immunology SSC of the ISTH. RESULTS: The PubMed/MEDLINE search revealed 1562 manuscripts; following review, 168 met inclusion criteria. Platelet response outcomes were reported in 141 studies, of which 57% did not use IWG definitions (using 21 distinct alternative platelet response schemes). Most randomized trials did not use IWG definitions, instead favoring platelet ≥50 × 109 /L to define response. Platelet ≥100 × 109 /L sustained for ≥6 months in the absence of therapy was the most common ITP remission definition. Bleeding outcomes were reported systematically in 41% of studies, which used 21 distinct reporting schemes. A plurality of adult studies used the World Health Organization Bleeding Scale and a plurality of pediatric studies used the Buchanan and Adix Score. HRQoL outcomes were reported in few studies (9%), which used a total of eight different HRQoL instruments. CONCLUSIONS: Despite prior attempts to standardize ITP outcome evaluation, wide variability in platelet, bleeding, and HRQoL outcomes remain. Most ITP studies did not systematically evaluate bleeding or HRQoL outcomes. Further standardization of outcome measurement in both pediatric and adult ITP is greatly needed.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H, Cronin A, Arnold DM, et al. Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. J Thromb Haemost. 2021. PMID: 33974336. doi:10.1111/jth.15366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。